Clozapine REMS removed, but neutropenia risk still requires monitoring, and some clinicians are still wary

Saying that the Risk Evaluation and Mitigation Strategies (REMS) program for clozapine may prevent access to treatment, the Food and Drug Administration (FDA) last year said the REMS is no longer necessary.

Publication Details

Journal
The Brown University Child & Adolescent Psychopharmacology Update
Published
2026-10-15
DOI
https://doi.org/10.1002/cpu.31104
Primary Topic
Schizophrenia research and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clozapine REMS removed, but neutropenia risk still requires monitoring, and some clinicians are still wary

The Brown University Child & Adolescent Psychopharmacology Update
Schizophrenia research and treatment
article

Clozapine REMS removed, but neutropenia risk still requires monitoring, and some clinicians are still wary

article en

Abstract

Saying that the Risk Evaluation and Mitigation Strategies (REMS) program for clozapine may prevent access to treatment, the Food and Drug Administration (FDA) last year said the REMS is no longer necessary.

The Brown University Child & Adolescent Psychopharmacology UpdateVol. 28(11)
Good health and well-being
Openalex Percentile: Top 13%
Schizophrenia research and treatment
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.